Brand Name

Iclusig

Generic Name
Ponatinib
View Brand Information
FDA approval date: December 14, 2012
Classification: Kinase Inhibitor
Form: Tablet

What is Iclusig (Ponatinib)?

Iclusig is indicated for the treatment of adult patients with: Chronic phase chronic myeloid leukemia with resistance or intolerance to at least two prior kinase inhibitors. Accelerated phase or blast phase CML or Philadelphia chromosome positive acute lymphoblastic leukemia for whom no other kinase inhibitors are indicated. T315I-positive CML or T315I-positive Ph+ ALL. Iclusig is a kinase inhibitor indicated for the treatment of adult patients with: Chronic phase chronic myeloid leukemia with resistance or intolerance to at least two prior kinase inhibitors. Accelerated phase or blast phase CML or Philadelphia chromosome positive acute lymphoblastic leukemia for whom no other kinase inhibitors are indicated. T315I-positive CML or T315I-positive Ph+ ALL. Limitations of Use : Iclusig is not indicated and is not recommended for the treatment of patients with newly diagnosed CP-CML.
Save this treatment for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms

Related Clinical Trials

A Phase II Study of Inotuzumab Ozogamicin Followed by Blinatumomab for Ph-Negative, CD22-Positive B-Lineage Acute Lymphoblastic Leukemia in Newly Diagnosed Older Adults or Adults With Relapsed or Refractory Disease

Summary: This phase II trial studies how well inotuzumab ozogamicin and blinatumomab with or without ponatinib work in treating patients with CD22-positive B-lineage acute lymphoblastic leukemia that is newly diagnosed, has come back after a period of improvement (recurrent), or does not respond to treatment (refractory). Inotuzumab ozogamicin is a monoclonal antibody, called inotuzumab, linked to a chemot...

An Open-Label, Single-Arm, Phase 1/2 Study Evaluating the Safety and Efficacy of Ponatinib for the Treatment of Recurrent or Refractory Leukemias, Lymphomas or Solid Tumors in Pediatric Participants

Summary: The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, and efficacy of ponatinib in children aged 1 to \< 18 years with advanced leukemias, lymphomas, and solid tumors.

Ponatinib as Second Line Therapy for Patients With Chronic Myeloid Leukemia in Chronic Phase Resistant or Intolerant to Imatinib, Dasatinib or Nilotinib

Summary: This phase II trial studies how well ponatinib hydrochloride works as second line therapy in treating patients with chronic myeloid leukemia in chronic phase that has not responded to initial treatment (first line) with imatinib mesylate, dasatinib, or nilotinib or cannot tolerate imatinib mesylate, dasatinib, or nilotinib. Ponatinib hydrochloride may stop or control the growth of cancer cells by ...